
Syndax Pharmaceuticals (SNDX) Stock Forecast & Price Target
Syndax Pharmaceuticals (SNDX) Analyst Ratings
Bulls say
Syndax Pharmaceuticals is well-positioned for future success with a strong pipeline of combination therapies in multiple cancer indications. Additionally, the company's financials are promising, with a steady increase in revenue and a solid cash flow. As the biopharmaceutical industry continues to grow, Syndax is primed to capitalize and potentially become a leader in the space.
Bears say
Syndax Pharmaceuticals is a clinical-stage biopharmaceutical company with a promising pipeline of combination cancer therapies. However, the company faces several challenges including a potentially limited market for its products, competition from other larger companies, and the need for additional funding. The success of Syndax's products will ultimately depend on its real-world efficacy and its ability to secure a strong market position in the highly competitive field of cancer therapy. Investors should closely monitor the company's progress in clinical trials and its financial situation to assess its potential for long-term success.
This aggregate rating is based on analysts' research of Syndax Pharmaceuticals and is not a guaranteed prediction by Public.com or investment advice.
Syndax Pharmaceuticals (SNDX) Analyst Forecast & Price Prediction
Start investing in Syndax Pharmaceuticals (SNDX)
Order type
Buy in
Order amount
Est. shares
0 shares